1. Scrip
  2. >>Business
  3. >>Deals

Boehringer Ingelheim Snaps Up Lupin's MEK Inhibitor For Difficult-To-Treat Cancers

 
• By John Davis and Anju Ghangurde

Boehringer Ingelheim intends to combine Lupin’s MEK inhibitor with its own KRAS inhibitors to target the oncogenic KRAS-RAF-MEK-ERK pathway, mutations in which drive many difficult-to-treat cancers.

Red signal
Cellular signaling pathway mutations are linked to cancer • Source: Shutterstock

In its second major out-licensing R&D deal of the past 12 months, Lupin Ltd. has signed a pact with Boehringer Ingelheim GmbH. The German group is to collaborate on the development of Lupin’s clinical-stage MEK inhibitor, LNP3794, for the treatment of difficult-to-treat KRAS-driven cancers.

The licensing, development and commercialization agreement, under which Lupin will receive an upfront of $20m, potential total milestones of $700m, and sales royalties, will involve the two companies evaluating LNP3794 in combination with Boehringer Ingelheim’s investigational KRAS

More from Deals

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.